Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Finished Goods (2020 - 2025)

Historic Finished Goods for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $20.3 million.

  • Cytek Biosciences' Finished Goods rose 4623.66% to $20.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.3 million, marking a year-over-year increase of 4623.66%. This contributed to the annual value of $14.8 million for FY2024, which is 87.73% up from last year.
  • Latest data reveals that Cytek Biosciences reported Finished Goods of $20.3 million as of Q3 2025, which was up 4623.66% from $16.9 million recorded in Q2 2025.
  • In the past 5 years, Cytek Biosciences' Finished Goods registered a high of $22.8 million during Q1 2023, and its lowest value of $9.1 million during Q2 2021.
  • Over the past 5 years, Cytek Biosciences' median Finished Goods value was $15.3 million (recorded in 2022), while the average stood at $15.7 million.
  • As far as peak fluctuations go, Cytek Biosciences' Finished Goods soared by 8631.25% in 2022, and later tumbled by 3435.62% in 2024.
  • Cytek Biosciences' Finished Goods (Quarter) stood at $12.6 million in 2021, then rose by 29.48% to $16.3 million in 2022, then dropped by 9.96% to $14.7 million in 2023, then increased by 0.88% to $14.8 million in 2024, then soared by 36.61% to $20.3 million in 2025.
  • Its last three reported values are $20.3 million in Q3 2025, $16.9 million for Q2 2025, and $15.2 million during Q1 2025.